MANISHA WADHWA: Open Payments
NPI 1851376354 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$22,297 in 60 payments from 14 companies in 2025. Trend: 2023 $4,148 · 2024 $39,935 · 2025 $22,297
Speaker / faculty: $13,950Consulting: $6,230Food & beverage: $1,215Travel & lodging: $903
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 23 | $14,931 |
| ABBVIE INC. | 8 | $6,737 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $132 |
| Supernus Pharmaceuticals, Inc. | 5 | $81 |
| Neurocrine BioSciences, Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| E.R. Squibb & Sons, L.L.C. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
Products named: LYBALVI, VRAYLAR, CAPLYTA, Qelbree, INGREZZA, Auvelity, FANAPT, COBENFY.
Industry payments across DE — which companies pay providers there.
